Nurtec ODT 75 MG tablet 8S
Ended Awarded Last action
- Contract number
- SPE2DR26F0L92
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,535
Award facts
- Contract value 100% obligated
- $9,535.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of NURTEC ODT 75 mg tablets (8-count units) with a contract value of $9,535.18. This is a firm fixed-price delivery order with an ultimate completion date of January 6, 2026, and represents a non-competed award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 comprehensive pharmaceutical supply agreement running through December 2026 that enables the contractor to provide a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs, particularly for military and veteran healthcare systems. The company's IDC vehicle with DLA encompasses specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains, supporting customers including the Defense Health Agency and U.S. Coast Guard. NURTEC ODT (ubrogepant) is a migraine treatment medication, reflecting the company's extensive portfolio of neurological and pain management pharmaceuticals supplied through federal contracts. This delivery order demonstrates the ongoing utilization of AmerisourceBergen's established DLA prime contract to fulfill specific pharmaceutical requirements within the Defense Health System's supply chain.
Quick answers
Who was awarded contract SPE2DR26F0L92?
SPE2DR26F0L92 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26F0L92 worth?
The government has obligated $9,535 on SPE2DR26F0L92.
Is contract SPE2DR26F0L92 an order under another contract?
Yes. SPE2DR26F0L92 is a delivery order under SPE2DR25D2207, an indefinite delivery contract.
Was contract SPE2DR26F0L92 competed?
The extent of competition for SPE2DR26F0L92 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award